incorporation is influenced by resistance to antifolate and fluoropyrimidine-based anti-cancer drugs in a drug-dependent manner and the underlying mechanisms appear to be cell-and drug-dependent. Glucose transport may be a useful marker of resistance to 5FU.
F]-FDG incorporation were measured in drug-resistant tumour cells generated by exposing H630 colon and MCF7 breast cancer cells to increasing concentrations of tomudex (raltitrexed) or 5-fluorouracil (5FU). Drug sensitivity was determined using the XTT assay: Tomudex-resistant (H630 TDX and MCF7 TDX ) cells were more than 40,000-fold less sensitive to tomudex than were the parental wild-type, H630 WT and MCF7 WT cells, respectively. 5FU-resistant (H630 R10 ) cells were 100-fold less sensitive than parental H630 WT cells to 5FU. As previously reported for 5FU-resistant MCF7 breast cancer cells, [ 5FU enters cells by facilitated diffusion and is then either catabolised (over 80%) to dihydroxyfluorouracil (1) or converted to a number of different molecules with anti-cancer activity: 5-fluoro-2'-deoxyuradine monophosphate (FdUMP) which is an inhibitor of thymidylate synthase (TS); 5-fluorouridine triphosphate which is incorporated into RNA and 5-fluoro-2'-uridine triphosphate which is incorporated into DNA causing strand termination.
The enzyme TS, which is an essential component in de novo pyrimidine synthesis and believed to be the primary target of 5FU therapy, is associated with resistance to 5FU via altered expression of this enzyme (2,3). Peters et al (3) reported an inverse relationship between TS expression levels in tumour tissue and response to 5FU in patients with colorectal cancer. Consequently studies have attempted patient stratification according to tumour TS expression as an avenue to combat 5FU resistance. However, the expression of TS in primary tumours has been found to be a poor prognostic biomarker after 5FU chemotherapy in patients with metastatic disease (4) . Discordant TS expression between primary and secondary tumours has been reported (5).
S-phase specific anti-cancer drugs, including tomudex and 5FU, exploit the increased proliferation rate and hence the higher percentage of cells in the S-phase to selectively target tumour cells. This mechanism of action of cytotoxic agents underpins their toxicity profile in normal tissues. Resistance to 5FU has been reported to be associated with cell cycle arrest and consequently, to increased numbers of cells in G 1 /G 0 or at the G 0 /S boundary resulting in slower growth (6) . Expression of glucose-handling proteins, including the Na-independent family of glucose transporters, GLUTS, has been shown to correlate with proliferation (7, 8) .
Glucose transport can be measured in vivo, non-invasively, using dynamic [ 18 F]-fluorodeoxyglucose (FDG)-positron emission tomography (PET) (9,10) from which K 1 and K 2 , rate constants for FDG transport into and out of the cell, respectively, can be measured. K 3 which is the rate constant for phosphorylation of FDG can also be determined. During the course of chemotherapy, drug-sensitive cells can be replaced by drug-resistant tumour cell populations. We previously reported that 5FU-resistant MCF7 breast cancer cells exhibited greatly enhanced glucose transport (11) compared with parental MCF7 cells, suggesting that enhanced glucose transport may be a feature of resistance to 5FU. In this study, we extended our research to the 5FU-resistant colorectal cell line, H630 R10 , and in view of the importance of TS inhibition on the mechanism of action of 5FU, we also measured glucose transport, hexokinase activity and [ 18 F]-FDG incorporation in 2 cell lines resistant to the specific TS inhibitor, tomudex (raltitrexed).
Materials and methods
Cell lines. The 5FU-resistant (H630 R10 ) colorectal cancer and tomudex-resistant colorectal (H630 TDX ) and breast cancer cell lines (MCF7 TDX ) which had been generated by continuously culturing the drug-sensitive parental wild-type cell lines, H630 WT , H630 WT and MCF7 WT , respectively in medium containing increasing concentrations of the drugs in a stepwise procedure, were a generous gift from Professor P.J. Johnstone (Department of Oncology, The Queen's University of Belfast). Cell lines were cultured in RPMI-1640 (Invitrogen, Paisley, UK) supplemented with 10% FCS, 50 U/ ml penicillin and 50 µg/ml streptomycin (complete medium).
To avoid an influence of the chemotherapy drug, all resistant cell lines were cultured in drug-free medium for 3 passages before any assays.
Cytotoxicity (XTT) assay.
In order to determine the sensitivity of resistant and wild-type cells to 5FU and tomudex, cells were seeded in 96-well plates and cultured in the presence of the respective drug concentrations (see below) for 72 h after which the relative cell content of each well was determined using the XTT assay. Briefly, cells were grown to 80% confluence in 75 cm 2 tissue culture flasks and detached using 0.05% trypsin and EDTA and seeded at a density of 2x10 5 cells per well following centrifugation and resuspension in complete medium. After 24-h incubation at 37˚C and 5% CO 2 , the drug was added and cells were incubated for 72 h. The range of drug concentrations was: 5FU: H630 WT , 1 to 100 µM; H630 R10 , 0.05 to 3 mM; tomudex: H630 WT , 0.1 to 50 nM; H630 TDX , 2.5 to 500 µM; MCF7 WT , 0.25 to 50 nM; and MCF7 TDX , 2.5 to 500 µM. Medium only (background) and vehicle controls were included on each plate following drug incubation, 50 µl of XTT/PMS (4.9 ml sodium 3-[1-phentlamino-carbonyl)-3,4-tetrazolium]-bis(4-methoxy-6-nitro) benzene sulfonic hydrate/0.1 ml 1.25 mM phenazine methosulfate) was added to each well and incubated for 2 h at 37˚C. Absorbance was measured at 450 and 690 nm in a 96-well plate spectrophotometer (Synergy HT; Biotek). IC 50 values were calculated using GraphPad Prism software. Triplicate independent experiments were performed with triplicate data points on each plate. 18 F]-FDG (37 KBq/ml) and cells were incubated at 37˚C for 20 min. The medium was removed and cells washed 5 times in 5 ml of PBS. Cells were trypsinised with 0.4 ml of 0.05% trypsin/EDTA, neutralised with 0.4 ml of complete medium and the cell suspension transferred to a microcentrifuge tube. Cell associated activity was measured in a well counter with a Scintillation Detector Interface (Oakfield Instruments Ltd., Eynsham, UK). After centrifugation at 400 x g for 5 min, the pellet was resuspended in 0.1 ml of NaOH (1 M) for 24 h at 37˚C. After neutralising with 0.1 ml of HCl (1 M), protein content was determined using the bicinchoninic acid protein assay kit (Sigma, Poole, UK).
[ 3 H-methyl]O-methyl-glucose ([ 3 H]-OMG) uptake (glucose transport)
. O-methyl-glucose (OMG) is transported by glucose transporters but is not metabolised. Thus, its initial rate of uptake after being adding to cells is considered to be a measure of glucose transport. Equilibration of OMG between the outside and inside of the cell is complete within seconds. To prevent the loss of OMG uptake into the cell during the incubation period, rapid washing with ice-cold PBS containing the glucose inhibitor, phloretin (100 µM), is required. Flasks of cells were seeded as described above ([ 18 F]-FDG incorporation assay). The medium was replaced 30 min prior to the OMG uptake assay with 1 ml of DMEM containing 5 mM glucose. The medium was discarded and replaced with 1 ml of DMEM containing 5 mM glucose and 37 KBq of [ Hexokinase activity. Flasks of cells were seeded as described above ([ 18 F]-FDG incorporation assay). Cells were trypsinised and neutralised with complete medium and centrifuged at 400 x g for 5 min at room temperature. Cells were washed in 1 ml PBS at 4˚C, centrifuged at 10,000 x g for 1 min, the supernatant was discarded and the cell pellet was snap-frozen in liquid nitrogen and stored at -80˚C.
Cell pellets were homogenised immediately prior to the assay. Cells were thawed then kept on ice and resuspended in 0.2 ml of homogenisation buffer (sucrose 0.25 mM, dithiothreitol 0.5 mM, aminohexanoic acid 1 mM, PMSF 1 mM, Tris-HCl 10 mM, pH 8.0) at 4˚C. The cell suspension was transferred to a 1 ml Dounce homogeniser (Fisher Scientific Ltd., Loughborough, UK) and homogenised on ice. After centrifugation for 10 min at 1,000 x g to pellet cell debris, hexokinase activity was measured in the supernatant.
Hexokinase activity was measured by adding 100 µl of supernatant to 0.9 ml of hexokinase assay buffer (dextrose 10 mM, NADPH + 0.4 mM, MgCl 2 10 mM, ATP 5 mM, Tris-HCl 100 mM, pH 8.0 and glucose-6-phosphatase 0.15 U) in a 1 ml cuvette at 37˚C. The change in absorbance at 340 nM due to the formation of NADPH was measured. The concentration of NADPH was determined from absorbance using the extinction co-efficient for NADPH of 6,220 mol
Statistical analysis. The Student's t-test was used to demonstrate significant differences between the means.
Results
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An example growth inhibitory curve is shown in Fig. 1 IC 50 values were derived from the dose-response curves shown in Fig. 1 using GraphPad Prism software. The IC 50 values of the parental cell lines are in parenthesis. 
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Discussion
A rapid means of determining drug response status of tumours to chemotherapy agents has been recognised as an essential clinical tool for decades (12) . Methods with the potential of determining potential responders include fresh tumour cell culture, predictive molecular biomarkers in biofluids prior to or at early treatment time-points and imaging biomarkers, such as those obtained with functional imaging modalities, for example PET. PET has the advantage that it is non-invasive and can be carried out serially. However, the relationship between [
18 F]-FDG-PET measurements and tumour characteristics including drug resistance remains unclear (13) . In this study, we demonstrate, using a colorectal cancer cell line, that resistance to 5FU is associated with decreased incorporation of [
18 F]-FDG and greatly increased glucose transport. The results are in agreement with our previous study on 5FU-resistant breast cancer cells. Conversely, resistance to tomudex is accompanied by increased [
18 F]-FDG incorporation whilst the correlation between glucose-transport and resistance to tomudex was found to be cell line-dependent.
Tomudex is a folate analogue which specifically inhibits TS activity. It enters the cell via folate transporters and is rapidly polyglutamated by the enzyme folylpolyglutamate synthase (FPGS) preventing its cellular efflux and increasing its affinity for TS. In common with resistance to 5FU, mechanisms of tomudex-resistance include increased TS expression, but also distinct mechanisms which include the down-regulation of the reduced folate transporter (14) and of FPGS activity (15) . 5FU also has distinct TS-independent mechanisms of resistance such as increased dUTPase, cell cycle perturbations and alterations in survival pathways such as NF-κB. We examined biochemical parameters that are measurable during a dynamic (17) and the rate of flux through the pentose phosphate pathway (18) . These mechanisms could underlie changes in glucose utilisation by 5FU and Tomudex-resistant tumour cells and these may be chemotherapy agent and tumour specific.
Although hexokinase activity was decreased in the 2 resistant cells, MCF7 TDX and H630 5FU , compared with the parental H630 TDX cells (present study) and 5FU-resistant MCF7 cells (11) did not exhibit any significant change in hexokinase activity. The lack of consistency in the change in hexokinase activity and type of drug resistance suggest that this is not a useful indicator of drug resistance. The difference in glucose transport by 5FU-resistant MCF7 breast cancer cells (11) and by H630 R10 colorectal cancer cells (present study) compared with wild-type cells is high; therefore, the rate constants, K 1 and K 2 , which measure glucose influx and efflux in dynamic FDG-PET, may be a particularly sensitive indicator of resistance to 5FU but not of resistance to tomudex. Recent studies (9, 10) have shown that K 1 can be a useful parameter demonstrating increased glucose transporter expression.
A number of previous studies (19) (20) (21) have examined the influence on tumour cell [ 18 F]-FDG accumulation of the overexpression of the P-glycoprotein (P-gp/MDR1), which is a plasma membrane protein that increases the rate of efflux of diverse anti-cancer drugs, including anthracyclines and taxanes. These studies have shown that [ 18 F]-FDG is a substrate for P-gp and consequently tumour cell P-gp expression is associated with low [ 18 F]-FDG accumulation. However, although reduced FDG uptake via enhanced P-gp efflux may be a mechanism of altered FDG dynamics in anthracyline-or taxane-resistant tumours, 5FU is not a P-gp substrate and therefore this is unlikely to be a mechanism in tumours resistant to this agent.
In summary, in this study, we show that resistance to tomudex is associated with increased [
18 F]-FDG incorpora- 
